Document is current

Article History

Received: 22 April 2024

Accepted: 8 September 2025

First Online: 21 November 2025

Declarations

:

: Ownership of the animals used in this study resided with Prisys Biotechnologies (Shanghai, China), who also undertook the animal work, which was approved by the Institutional Animal Care and Use Committee under study number 2015-PS11-002 (license code No. 204 0000037). UCB representatives (including an animal care and welfare officer) assessed facilities and procedures prior to the study start to ensure best practice animal welfare in accordance with United Kingdom (UK) Home Office guidelines and the Animal Scientific Procedures Act 1986 (ASPL). A UCB representative was present during all animal experiments to ensure compliance with ASPL. The study is reported in accordance with the ARRIVE guidelines. The human skin biopsy study was a research collaboration with the University of Oxford and was approved by the South Central - Oxford B Research Ethics Committee (reference 16/SC/0457), in accordance with the Declaration of Helsinki. All participants provided informed consent.

: Not applicable.

: RB is an employee of UCB who in-licensed zampilimab and holds/has access to stock options. LH, TS, GIJ, and TSJ were employees of UCB at the time the work was completed and held/had access to stock options during this time. TSJ is an inventor on patent WO2013/175229 A1 (Anti-transglutaminase 2 antibodies) relating to the discovery and humanization of zampilimab. AB was an employee of OracleBio at the time the study was conducted. AR was an employee of Veramed at the time the study was conducted. GO is supported by the UK Medical Research Council and was in receipt of UCB research funding administered through the University of Oxford.